Contact Us
Subscribe
E-Edition

56°

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
Sports
Obits
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Subscribe
Archives
Best of 2025
Pet Contest

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Adverum Biotechnologies, Inc. - Common Stock (NQ:ADVM)

4.280 +0.020 (+0.47%)

Streaming Delayed Price Updated: 9:34 AM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Adverum Biotechnologies, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023 ↗

March 07, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 28, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 26, 2022

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 47.9% to $0.31 during Wednesday's pre-market session. The company's market cap stands at $11.8 million.

Via Benzinga

Adverum Posts New Data From Wet AMD Gene Therapy Trial ↗

July 15, 2022

Via Benzinga

Adverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022 ↗

July 07, 2022

Via Benzinga

Adverum's Data at ASGCT Further Supports Phase 2 Development Plans For Wet-AMD Gene Therapy ↗

May 18, 2022

Via Benzinga

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary ↗

September 14, 2022

Via Benzinga

Adverum Commences Mid-Stage Chronic Eye Disorder Candidate Study ↗

September 14, 2022

Adverum Biotechnologies (NASDAQ: ADVM) dosed first subject in the LUNA Phase 2 trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet age-related...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 26, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Signs Off Cancer Therapy Trials For NexImmune, Omega Therapeutics, Endo To Develop Rare Hereditary Skin Disease Candidate ↗

July 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill ↗

July 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Adverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMD ↗

May 02, 2022

Via Benzinga

Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday ↗

July 18, 2022

Gainers United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Friday. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

July 07, 2022

Good morning, trader! We're taking a look at the biggest pre-market stock movers for Thursday that investors need to know about!

Via InvestorPlace

Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session ↗

July 15, 2022

Gainers United Maritime Corporation (NASDAQ: USEA) shares jumped 180.9% to $6.19. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering on Wednesday.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 06, 2022

Gainers

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022 ↗

July 07, 2022

Upgrades

Via Benzinga

Short Volatility Alert: Adverum Biotechnologies, Inc. ↗

June 15, 2022

On Tuesday, shares of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) experienced volatile short activity. After the activity, the stock price went down -2.74% to $0.9259. The overall sentiment for ADVM...

Via Benzinga

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study ↗

June 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

3 Stocks Under $3 Insiders Are Aggressively Buying ↗

April 25, 2022

US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 18, 2022

Gainers Natus Medical (NASDAQ:NTUS) stock rose 28.3% to $33.42 during Monday's pre-market session. The market value of their outstanding shares is at $1.1 billion....

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

April 12, 2022

Good morning! It's time for another dive into the market this morning with a look at the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More ↗

April 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD ↗

April 07, 2022

Adverum Biotechnologies Inc (NASDAQ: ADVM) received feedback via a

Via Benzinga

Adverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD ↗

December 21, 2021

Adverum Biotechnologies Inc (NASDAQ: ADVM) plans to conduct a Phase 2 trial of ADVM-022 in wet AMD at 2 X 10^11 vg/eye dose and a new lower 6 X 10^10 vg/eye dose,...

Via Benzinga

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

44 Biggest Movers From Yesterday ↗

October 05, 2021

Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of...

Via Benzinga

Mid-Afternoon Market Update: Dow Drops 375 Points; Elmira Savings Bank Shares Spike Higher ↗

October 04, 2021

Toward the end of trading Monday, the Dow traded down 1.09% to 33,951.17 while the NASDAQ fell 2.28% to 14,234.17. The S&P also fell, dropping 1.49% to 4,292.00. The U.S. has...

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

starkvilledailynews.com
304 E. Lampkin Street,
Starkville, MS 39759
Phone: 662-323-1642
Email: editor@starkvilledailynews.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Adverum Biotechnologies, Inc. - Common Stock (NQ:ADVM)

Headline News about Adverum Biotechnologies, Inc. - Common Stock

Sections

Services

Follow Us